AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8886295 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment
Number of subjects: 0
Study 8886295 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 1905799 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate treatment with oral penicillin V
Number of subjects: 306
Study 1905799 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment with placebo followed by penicillin V
Number of subjects: 306
Study 6342637 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupirtine maleate 100 mg
Number of subjects: 50
Study 6342637 — intervention group
Group type: COMPARATOR
Intervention: Dihydrocodeine 60 mg
Number of subjects: 50
Study 31907013 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Health Choices primary school resources (textbooks, exercise books, teachers' guide)
Number of subjects: 10813
Study 31907013 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10813
Study 31907013 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed Health Choices primary school resources
Number of subjects: 10813
Study 31094225 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 and bemarituzumab
Number of subjects: 0
Study 31094225 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX6 and placebo
Number of subjects: 0
Study 25733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Depuy Discover artificial disc
Number of subjects: 153
Study 25733022 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion (ACDF) with iliac crest bone graft and plating
Number of subjects: 153
Study 25733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary surgery
Number of subjects: 153
Study 25733022 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 153
Study 25733022 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D and visual analog scale
Number of subjects: 153
Study 23317960 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month thrice-weekly directly observed treatment (DOT) regimen for tuberculous peripheral adenopathy
Number of subjects: 551
Study 23317960 — intervention group
Group type: COMPARATOR
Intervention: Extended treatment up to 9 months
Number of subjects: 551
Study 23317960 — intervention group
Group type: COMPARATOR
Intervention: Observation without additional treatment
Number of subjects: 551
Study 20852005 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 124
Study 20852005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 20852005 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin and Placebo
Number of subjects: 124
Study 19243767 — intervention group
Group type: COMPARATOR
Intervention: NSAID (diclofenac sodium, 25 mg 3 times daily) and omeprazole (20 mg once daily)
Number of subjects: 34
Study 19243767 — intervention group
Group type: EXPERIMENTAL
Intervention: PG (misoprostol, 200 microg 3 times daily) with NSAID and omeprazole
Number of subjects: 34
Study 16739326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR (doxifluridine) at 800 mg/body daily for 3 years
Number of subjects: 87
Study 16739326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR (doxifluridine) at 800 mg/body daily for 1 year
Number of subjects: 87
Study 16739326 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy with gosereline acetate (3.6 mg/body, monthly) for pre-menopausal patients
Number of subjects: 87
Study 16739326 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine therapy with tamoxifen (20 mg/day, daily) for post-menopausal patients
Number of subjects: 87
Study 16739326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'-DFUR (doxifluridine)
Number of subjects: 87
Study 14710214 — intervention group
Group type: EXPERIMENTAL
Intervention: Estramustine phosphate (EMP) and vinblastine (VBL) combination chemotherapy
Number of subjects: 92
Study 14710214 — intervention group
Group type: COMPARATOR
Intervention: Estramustine phosphate (EMP) alone
Number of subjects: 92
Study 11846062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential high-dose methotrexate (1 g/m2, day 1), fluorouracil (1.5 g/m2, day 1), leucovorin (15 mg/m2, days 2-4), and doxorubicin (30 mg/m2, day 15), repeated at a 28-day interval, followed by radical surgery
Number of subjects: 20
Study 1408299 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard program with additional psychological components
Number of subjects: 45
Study 1408299 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient rehabilitation program
Number of subjects: 45
Study 3936558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release formulations of valproic acid (VPA)
Number of subjects: 6
Study 3936558 — intervention group
Group type: COMPARATOR
Intervention: Standard tablet of valproic acid (VPA)
Number of subjects: 6
Study 3936558 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (i.v.) preparation of valproic acid (VPA)
Number of subjects: 6
Study 30257756 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 PRP injections in the subacromial space at 1-week intervals
Number of subjects: 50
Study 30257756 — intervention group
Group type: COMPARATOR
Intervention: Single depot corticosteroid injection in the subacromial space
Number of subjects: 50
Study 27280016 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 0
Study 24991815 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-uninfected men (HIV‐)
Number of subjects: 159
Study 24991815 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men using HAART (HIV+/HAART+)
Number of subjects: 159
Study 24991815 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men not using HAART (HIV+/HAART‐)
Number of subjects: 159
Study 24991815 — intervention group
Group type: COMPARATOR
Intervention: HIV-infected men
Number of subjects: 159
Study 23672220 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose chewable tablet
Number of subjects: 234
Study 23672220 — intervention group
Group type: COMPARATOR
Intervention: Acarbose treatment (control group)
Number of subjects: 234
Study 23672220 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 234
Study 20354531 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation (5-fluorouracil and mitomycin C)
Number of subjects: 577
Study 20354531 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 577
Study 18279686 — intervention group
Group type: EXPERIMENTAL
Intervention: EE-betadex clathrate/drsp tablet
Number of subjects: 18
Study 18279686 — intervention group
Group type: COMPARATOR
Intervention: EE/drsp tablet
Number of subjects: 18
Study 18279686 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline suspension
Number of subjects: 18
Study 16178134 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.07% cetylpyridinium chloride (CPC) mouthrinse (Crest Pro‐Health Rinse)
Number of subjects: 273
Study 16178134 — intervention group
Group type: COMPARATOR
Intervention: Cosmetic rinse control (Scope)
Number of subjects: 273
Study 12826042 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant + dexamethasone + ondansetron on day 1 and aprepitant + dexamethasone on days 2-5
Number of subjects: 0
Study 12826042 — intervention group
Group type: COMPARATOR
Intervention: Standard antiemetic therapy (dexamethasone and ondansetron on day 1 and dexamethasone on days 2-5)
Number of subjects: 0
Study 10855533 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (1.2 pmol/l x kg(‐1) x min(‐1))
Number of subjects: 8
Study 10855533 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 8841058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive orthoptic screening by orthoptists
Number of subjects: 0
Study 8841058 — intervention group
Group type: COMPARATOR
Intervention: Usual non-specialist screening
Number of subjects: 0
Study 2004541 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 400 micrograms once daily
Number of subjects: 248
Study 2004541 — intervention group
Group type: COMPARATOR
Intervention: Intranasal budesonide 200 micrograms twice daily
Number of subjects: 248
Study 4088460 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.7 g/kg)
Number of subjects: 0
Study 31437413 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based peer support until 4 months postpartum
Number of subjects: 114
Study 31437413 — intervention group
Group type: COMPARATOR
Intervention: Conventional support
Number of subjects: 114
Study 30107003 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment with high pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 0
Study 30107003 — intervention group
Group type: EXPERIMENTAL
Intervention: High pre-treatment levels of 25-hydroxyvitamin D (25(OH)D)
Number of subjects: 0
Study 30107003 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine treatment
Number of subjects: 0
Study 29933533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sancai powder
Number of subjects: 132
Study 29933533 — intervention group
Group type: COMPARATOR
Intervention: Metformin (1500 mg/day)
Number of subjects: 132
Study 29933533 — intervention group
Group type: EXPERIMENTAL
Intervention: Sancai powder and Metformin
Number of subjects: 132
Study 22540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) twice/week for 21 weeks (STW)
Number of subjects: 135
Study 22540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) once/week for 21 weeks (STWx1)
Number of subjects: 135
Study 22540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST) twice/week for 21 weeks (STWx2)
Number of subjects: 135
Study 22540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (STM) twice/week for 21 weeks
Number of subjects: 135
Study 22540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (STMx1) once/week for 21 weeks
Number of subjects: 135
Study 22540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (STMx2) twice/week for 21 weeks
Number of subjects: 135
Study 22540957 — intervention group
Group type: COMPARATOR
Intervention: Control group (CW and CM)
Number of subjects: 135
Study 21940766 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERAs)
Number of subjects: 1130
Study 21940766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1130
Study 22403986 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.0% arginine, calcium carbonate, and 1450 ppm fluoride dentifrice
Number of subjects: 12
Study 22403986 — intervention group
Group type: COMPARATOR
Intervention: 8% strontium acetate and 1040 ppm fluoride dentifrice
Number of subjects: 12
Study 18971722 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstructive surgery for prominent ears
Number of subjects: 42
Study 18971722 — intervention group
Group type: COMPARATOR
Intervention: Leg lengthening surgery (comparison group)
Number of subjects: 42
Study 18971722 — intervention group
Group type: COMPARATOR
Intervention: Control group (schoolchildren)
Number of subjects: 42
Study 16430676 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation knee brace for 12 weeks post-operatively
Number of subjects: 60
Study 16430676 — intervention group
Group type: COMPARATOR
Intervention: No brace, mobilized immediately, crutches discarded 2 weeks post-operatively
Number of subjects: 60
Study 12618584 — intervention group
Group type: EXPERIMENTAL
Intervention: Elite premenarcheal gymnasts
Number of subjects: 60
Study 12618584 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 60
Study 10719950 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium (500 microg/kg)
Number of subjects: 18
Study 10719950 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine (50 microg/kg)
Number of subjects: 18
Study 10719950 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 18
Study 8874675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy (PHT)
Number of subjects: 0
Study 8874675 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture therapy (AP)
Number of subjects: 0
Study 1343111 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (oral solution, conventional tablets, extended release tablets)
Number of subjects: 140
Study 1343111 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (various formulations)
Number of subjects: 140
Study 6589119 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-cycled ventilation
Number of subjects: 0
Study 6589119 — intervention group
Group type: COMPARATOR
Intervention: High-frequency jet ventilation
Number of subjects: 0
Study 6589119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both types of ventilator
Number of subjects: 0
Study 30049247 — intervention group
Group type: EXPERIMENTAL
Intervention: Openly hostile resistance at Session 10
Number of subjects: 71
Study 30049247 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostile resistance at Session 2
Number of subjects: 71
Study 29587662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% colchicine cream for 10 days
Number of subjects: 36
Study 29587662 — intervention group
Group type: COMPARATOR
Intervention: MAL-PDT (methyl aminolevulinate photodynamic therapy)
Number of subjects: 36
Study 27508135 — intervention group
Group type: EXPERIMENTAL
Intervention: Apo‐Cetirizine 10 mg tablet daily
Number of subjects: 54
Study 27508135 — intervention group
Group type: COMPARATOR
Intervention: Sequential regimen of cetirizine 10 mg tablet, loratadine 10 mg tablet and chlorpheniramine 4 mg tablet, one tablet each day
Number of subjects: 54
Study 24853544 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquaphor
Number of subjects: 491
Study 24853544 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunflower seed oil
Number of subjects: 491
Study 24853544 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 491
Study 23145952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline (100 mg initial dose, then 50 mg IV every 12 hrs)
Number of subjects: 531
Study 23145952 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam (1.5-3 g IV every 6 hrs) or Amoxicillin-clavulanate (1.2 g IV every 6-8 hrs)
Number of subjects: 531
Study 23145952 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 531
Study 23145952 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-sulbactam or Amoxicillin-clavulanate
Number of subjects: 531
Study 20737166 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric cycling (151 ± 32 W, 487 ± 107 s)
Number of subjects: 18
Study 20737166 — intervention group
Group type: COMPARATOR
Intervention: Concentric cycling (148 ± 21 W, 488 ± 79 s)
Number of subjects: 18
Study 18565418 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 0
Study 18565418 — intervention group
Group type: COMPARATOR
Intervention: Best Medical Management with Aspirin (ASA)
Number of subjects: 0
Study 18565418 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive carotid angioplasty and stenting
Number of subjects: 0
Study 16122072 — intervention group
Group type: COMPARATOR
Intervention: Thin smear microscopy (clinical study)
Number of subjects: 0
Study 16122072 — intervention group
Group type: COMPARATOR
Intervention: Thin smear microscopy (field trial)
Number of subjects: 0
Study 16122072 — intervention group
Group type: COMPARATOR
Intervention: Thick smear microscopy (field trial)
Number of subjects: 0
Study 12100150 — intervention group
Group type: EXPERIMENTAL
Intervention: ACVB regimen (doxorubicin, cyclophosphamide, vindesine, bleomycin, prednisone)
Number of subjects: 2210
Study 10457543 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg oral dose of SR 46349B (5-HT2 antagonist) administered three hours before bedtime
Number of subjects: 0
Study 10457543 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 8527534 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (100 mg twice daily for 3 days)
Number of subjects: 116
Study 8527534 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (500 mg four times daily for 7 days)
Number of subjects: 116
Study 2254723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified Conventional Treatment (ICT)
Number of subjects: 97
Study 2254723 — intervention group
Group type: COMPARATOR
Intervention: Regular Treatment (RT)
Number of subjects: 97
Study 6989436 — intervention group
Group type: EXPERIMENTAL
Intervention: Early injection of insulin (30 minutes before breakfast)
Number of subjects: 9
Study 6989436 — intervention group
Group type: COMPARATOR
Intervention: Late injection of insulin (5 minutes before breakfast)
Number of subjects: 9
Study 6989436 — intervention group
Group type: EXPERIMENTAL
Intervention: Early injection of insulin
Number of subjects: 9
Study 6989436 — intervention group
Group type: COMPARATOR
Intervention: Late injection of insulin
Number of subjects: 9
Study 6989436 — intervention group
Group type: EXPERIMENTAL
Intervention: Both injection regimens
Number of subjects: 9
Study 31038792 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (liquid diet after 1 hour, solid diet after 4 hours)
Number of subjects: 101
Study 31038792 — intervention group
Group type: COMPARATOR
Intervention: Delayed feeding (fasting for 4 hours, liquid diet until 24 hours, soft diet for 48 hours, solid diet after 72 hours)
Number of subjects: 101
Study 27716673 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO robotic pet therapy
Number of subjects: 61
Study 27716673 — intervention group
Group type: COMPARATOR
Intervention: Standard activity programs (Control)
Number of subjects: 61
Study 25672376 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and chemotherapy
Number of subjects: 123
Study 25672376 — intervention group
Group type: EXPERIMENTAL
Intervention: Usable DWI data
Number of subjects: 123
Study 25672376 — intervention group
Group type: EXPERIMENTAL
Intervention: High quality DWI data
Number of subjects: 123
Study 25672376 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI quality evaluation
Number of subjects: 123
Study 24030420 — intervention group
Group type: EXPERIMENTAL
Intervention: Transendocardial CD34(+) cell delivery
Number of subjects: 40
Study 24030420 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary CD34(+) cell delivery
Number of subjects: 40
Study 21601010 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Number of subjects: 0
Study 19800047 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs associated with COPD susceptibility
Number of subjects: 813
Study 19800047 — intervention group
Group type: EXPERIMENTAL
Intervention: Three SNPs in the IREB2 gene
Number of subjects: 813
Study 19800047 — intervention group
Group type: EXPERIMENTAL
Intervention: Four other IREB2 SNPs
Number of subjects: 813
Study 19800047 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven IREB2 SNPs
Number of subjects: 813
Study 19800047 — intervention group
Group type: EXPERIMENTAL
Intervention: Main phenotype of interest
Number of subjects: 813
Study 19800047 — intervention group
Group type: EXPERIMENTAL
Intervention: IREB2 protein and mRNA
Number of subjects: 813
Study 15930028 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg GTP
Number of subjects: 124
Study 15930028 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg GTP
Number of subjects: 124
Study 15930028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 12918649 — intervention group
Group type: EXPERIMENTAL
Intervention: Spending 120 minutes each week in restorative activities involving nature
Number of subjects: 0
Study 12918649 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 11044540 — intervention group
Group type: EXPERIMENTAL
Intervention: beta(2)-adrenergic agonist therapy (clenbuterol)
Number of subjects: 61
Study 11044540 — intervention group
Group type: COMPARATOR
Intervention: physiological therapy (PT)
Number of subjects: 61
Study 11044540 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of beta(2)-adrenergic agonist and PT
Number of subjects: 61
Study 9075142 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal allograft recipients
Number of subjects: 33
Study 8364133 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc therapy
Number of subjects: 13
Study 8364133 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study 3554590 — intervention group
Group type: EXPERIMENTAL
Intervention: dalargin
Number of subjects: 180
Study 3554590 — intervention group
Group type: COMPARATOR
Intervention: tagamet
Number of subjects: 180
Study 3554590 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 29182498 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryogen-cooled monopolar radiofrequency therapy (CMRF) at 90 J/cm2
Number of subjects: 108
Study 29182498 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (≤1 J/cm2)
Number of subjects: 108
Study 27853272 — intervention group
Group type: EXPERIMENTAL
Intervention: Cupping therapy
Number of subjects: 141
Study 25436350 — intervention group
Group type: EXPERIMENTAL
Intervention: QUEST questionnaire
Number of subjects: 70
Study 25436350 — intervention group
Group type: COMPARATOR
Intervention: GerdQ questionnaire
Number of subjects: 70
Study 23690533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet
Number of subjects: 318
Study 23690533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 318
Study 23690533 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 318
Study 23690533 — intervention group
Group type: COMPARATOR
Intervention: All diets
Number of subjects: 318
Study 20857010 — intervention group
Group type: EXPERIMENTAL
Intervention: CloSYS II
Number of subjects: 90
Study 20857010 — intervention group
Group type: EXPERIMENTAL
Intervention: Corsodyl
Number of subjects: 90
Study 20857010 — intervention group
Group type: COMPARATOR
Intervention: Polident
Number of subjects: 90
Study 20857010 — intervention group
Group type: COMPARATOR
Intervention: Efferdent
Number of subjects: 90
Study 20857010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fittydent
Number of subjects: 90
Study 19675681 — intervention group
Group type: EXPERIMENTAL
Intervention: History and Physical Examination (H&P) estimates of filling pressures and cardiac index
Number of subjects: 388